D E Lilienfeld

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Mortality from primary pulmonary hypertension in the United States, 1979-1996
    D E Lilienfeld
    Department of Medicine, School of Medicine Dr Rubin, University of California at San Diego, USA
    Chest 117:796-800. 2000
  2. ncbi Decreasing mortality from pulmonary embolism in the United States, 1979-1996
    D E Lilienfeld
    Int J Epidemiol 29:465-9. 2000
  3. ncbi Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting
    David E Lilienfeld
    Department of Global Epidemiology and Outcomes Research, Pharmaceutical Research Institute, The Bristol Myers Squibb Company, Princeton, NJ 08543 5400, USA
    Pharmacoepidemiol Drug Saf 13:381-5. 2004
  4. ncbi The need for a population-based surveillance system for liver disease in the United States
    Anila Verma
    Novartis, Inc, Senior Epidemiologist, Clinical Safety and Epidemiology, One Health Plaza, East Hanover, NJ, USA
    Pharmacoepidemiol Drug Saf 13:821-4. 2004
  5. ncbi A challenge to the data miners
    David E Lilienfeld
    InterMune, Inc, Drug Safety and Pharmacovigilance, 3280 Bayshore Building, Brisbane, CA 94005, USA
    Pharmacoepidemiol Drug Saf 13:881-4. 2004
  6. ncbi The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901-1902
    David E Lilienfeld
    Perspect Biol Med 51:188-98. 2008

Collaborators

  • Anila Verma

Detail Information

Publications6

  1. ncbi Mortality from primary pulmonary hypertension in the United States, 1979-1996
    D E Lilienfeld
    Department of Medicine, School of Medicine Dr Rubin, University of California at San Diego, USA
    Chest 117:796-800. 2000
    ..To determine whether primary pulmonary hypertension mortality in the United States increased since 1979 coincident with the introduction of anorexigens...
  2. ncbi Decreasing mortality from pulmonary embolism in the United States, 1979-1996
    D E Lilienfeld
    Int J Epidemiol 29:465-9. 2000
    ..Previous investigations had identified several mortality contrasts in pulmonary embolism mortality among US residents. These findings had been made in the context of a trend of increasing rates during 1962-1984...
  3. ncbi Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting
    David E Lilienfeld
    Department of Global Epidemiology and Outcomes Research, Pharmaceutical Research Institute, The Bristol Myers Squibb Company, Princeton, NJ 08543 5400, USA
    Pharmacoepidemiol Drug Saf 13:381-5. 2004
    ....
  4. ncbi The need for a population-based surveillance system for liver disease in the United States
    Anila Verma
    Novartis, Inc, Senior Epidemiologist, Clinical Safety and Epidemiology, One Health Plaza, East Hanover, NJ, USA
    Pharmacoepidemiol Drug Saf 13:821-4. 2004
  5. ncbi A challenge to the data miners
    David E Lilienfeld
    InterMune, Inc, Drug Safety and Pharmacovigilance, 3280 Bayshore Building, Brisbane, CA 94005, USA
    Pharmacoepidemiol Drug Saf 13:881-4. 2004
  6. ncbi The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901-1902
    David E Lilienfeld
    Perspect Biol Med 51:188-98. 2008
    ..That power, welcomed by manufacturers to restore the public's trust in their products, was enhanced in the 1906 Food and Drug Act, which created the Food and Drug Administration...